Parenteral Iron Therapy for Pediatric Patients

被引:0
|
作者
Mantadakis, Elpis [1 ]
Alexiadou, Sonia [1 ]
Zikidou, Panagiota [1 ]
机构
[1] Univ Gen Hosp Alexandroupolis, Dept Pediat, Hematol Oncol Unit, Alexandroupolis 68100, Greece
来源
HEMATO | 2024年 / 5卷 / 01期
关键词
iron deficiency; iron deficiency anemia; intravenous iron; iron sucrose; ferric carboxymaltose; iron isomaltoside; inflammatory bowel diseases; INFLAMMATORY-BOWEL-DISEASE; MOLECULAR-WEIGHT IRON; DEFICIENCY ANEMIA; FERRIC CARBOXYMALTOSE; CHILDREN; EFFICACY; MANAGEMENT; DEXTRAN; SAFETY; HYPERSENSITIVITY;
D O I
10.3390/hemato5010005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Iron deficiency (ID) is by far the most common nutritional disorder in developing and developed countries. When left untreated, ID leads to anemia. Although the usually recommended treatment for iron deficiency anemia (IDA) is oral iron therapy with countless products, such therapy necessitates administration for >3-6 months with questionable patient compliance since most oral iron products have an unpleasant metallic aftertaste and cause intestinal side effects. In addition, in certain gastrointestinal conditions, such as inflammatory bowel diseases or untreated gluten-sensitive enteropathy, oral iron therapy is contraindicated or unsuccessful. Intravenous iron is considered safe in adults, where adverse events are mild and easily managed. The experience with parenteral iron in children is much more limited, and many pediatricians appear reluctant to use it because of uncorroborated fears of serious anaphylactic reactions. In the current article, we thoroughly review the available pediatric literature on the use of all commercially available parenteral iron products except ferumoxytol, which was recently removed from the market. We conclude that parenteral iron appears to be safe in children; it works faster than oral iron, and the newer third-generation products allow replacement of the total iron deficit in a single sitting.
引用
收藏
页码:35 / 47
页数:13
相关论文
共 50 条
  • [1] IRON THERAPY IN HEMODIALYSIS PATIENTS - ORAL OR PARENTERAL
    WINNEY, RJ
    SWAINSON, CP
    PARKER, A
    BONE, JM
    ROBSON, JS
    KIDNEY INTERNATIONAL, 1977, 12 (01) : 88 - 88
  • [2] Parenteral iron therapy
    Kaplinsky, Chaim
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2008, 10 (05): : 372 - 373
  • [3] PARENTERAL IRON THERAPY
    DOYLE, DJ
    M D COMPUTING, 1989, 6 (05): : 304 - 304
  • [4] PARENTERAL IRON THERAPY
    不详
    BMJ-BRITISH MEDICAL JOURNAL, 1966, 2 (5508): : 286 - +
  • [5] Parenteral Iron Sucrose Improves Iron Biomarkers in Pediatric Heart Failure Patients With Iron Deficiency
    Lin, Michael J.
    Kronmal, Richard
    Otero, Jessica
    Kirk, Christa
    Albers, Erin L.
    Hong, Borah
    Friedland-Little, Joshua
    Kemna, Mariska
    Law, Yuk M.
    CIRCULATION, 2020, 142
  • [6] ORAL AND PARENTERAL IRON THERAPY
    PRIBILLA, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1970, 95 (35) : 1789 - +
  • [7] Parenteral iron therapy options
    Silverstein, SB
    Rodgers, GM
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 76 (01) : 74 - 78
  • [8] PARENTERAL IRON DEXTRAN THERAPY
    KUMPF, VJ
    HOLLAND, EG
    DICP-THE ANNALS OF PHARMACOTHERAPY, 1990, 24 (02): : 162 - 166
  • [9] Tolerability and efficacy of parenteral iron therapy in haemodialysis patients.
    Moniem, KA
    Bhandari, S
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 705A - 705A
  • [10] EFFECT OF ORAL AND PARENTERAL IRON THERAPY IN PATIENTS ON CHRONIC HEMODIALYSIS
    MAHER, CC
    BILINSKY, RT
    LEE, HB
    MITRA, S
    KIENSTRA, R
    KIDNEY INTERNATIONAL, 1975, 8 (06) : 429 - 429